英国NHS倡导,使用水凝胶降低放射治疗前列腺癌患者的副作用

2019-05-16 MedSci MedSci原创

前列腺癌是男性中最常见的癌症,每年在英格兰新诊断出的病例超过40000例。当足够早地发现前列腺癌时,放射治疗是一种非常有效的治疗方法,高能X射线靶向前列腺,杀死癌细胞并阻止扩散。然而附近的健康器官也会受到影响。SpaceOAR水凝胶充当间隔物,通过临时将其远离治疗中使用的高剂量辐射,减少治疗期间损伤直肠的辐射量。水凝胶作为NHS特定创新计划的一部分得到资助,该计划在过去三年中已经使超过300000

前列腺癌是男性中最常见的癌症,每年在英格兰新诊断出的病例超过40000例。当足够早地发现前列腺癌时,放射治疗是一种非常有效的治疗方法,高能X射线靶向前列腺,杀死癌细胞并阻止扩散。

然而附近的健康器官也会受到影响。SpaceOAR水凝胶充当间隔物,通过临时将其远离治疗中使用的高剂量辐射,减少治疗期间损伤直肠的辐射量。

水凝胶作为NHS特定创新计划的一部分得到资助,该计划在过去三年中已经使超过300000名患者受益。现在鼓励英国医院为所有可能受益的患者使用其水凝胶装置,使放射治疗成为许多男性更安全、痛苦更少的治疗选择。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-18 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-18 lishizhe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-18 小几洁
  6. [GetPortalCommentsPageByObjectIdResponse(id=1824318, encodeId=9b1018243188c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Dec 16 19:40:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811207, encodeId=1654181120e85, content=<a href='/topic/show?id=34508e085ea' target=_blank style='color:#2F92EE;'>#英国NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87085, encryptionId=34508e085ea, topicName=英国NHS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Mon Mar 23 14:40:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308050, encodeId=f9b213080505a, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461020, encodeId=804a146102039, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515275, encodeId=272315152e5c6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat May 18 12:40:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040457, encodeId=e611104045ee2, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 17 00:40:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Urology:泌尿专家实践结构与前列腺癌治疗花费

最近,有研究人员调查了泌尿专家实践结构对男性前列腺癌治疗花费的影响。研究人员假设了3个泌尿专家实践因素能够影响前列腺癌治疗的花费:泌尿科医师参与多专科组(MSG)、单独的专业泌尿外科组的实践规模和放射治疗强度(IMRT)所有权。研究人员鉴定了35929名新诊断为前列腺癌的男性,他们由6381名泌尿科专家进行诊治。研究发现,新诊断前列腺癌男性的医疗花费在MSGs组中显著更低($19,181 v. $

Mol Cancer Ther:Notch1活性缺失能够抑制前列腺癌的生长和转移

前列腺癌在男性相关死亡原因中仍旧占据主导地位。患有恶性疾病的患者基本都要经历激素阻断治疗。虽然起始的治疗非常有效,这些男性通常在未来2-3年会发展至致死的、去势抵抗性前列腺癌。去势抵抗性前列腺癌的标准治疗方法包括第二代抗雄激素治疗,但是只能延长患者寿命几个月。因此,加深对抵抗性产生机理的理解是必要的,最终目的就是要开发出恶性前列腺癌的新疗法。最近,有研究人员鉴定了Notch1作为前列腺癌的治疗靶标

Prostate Cancer P D:前列腺癌患者前列腺切除术后男性的死亡日期和死因调查

国家死亡指数(NDI)是一个集中式的数据库,包含了死亡证明相关信息,这些信息被健康和医疗调查人员用来参考确定人口动态统计情况。然而,该数据库经常包含错误的死因。由于NDI依赖于前列腺癌(PC)患者根治性前列腺切除(RP)相关研究的治疗结果数据,最近,有研究人员通过参考SEARCH数据库的死亡数据来确定NDI数据的可靠性。研究发现,在SEARCH中共有1312名男性死亡,然而,NDI却报道这些男性的

Prostate:前列腺癌中胞外囊泡来源蛋白组织差异表达分析

前列腺癌(PCa)和正常前列腺细胞系中的胞外囊泡(EVs)蛋白组分析能够促使人们发现PCa新的候选标记。这些蛋白包括了核输出蛋白XPO1(也称为CRM1)、EV相关的PDCD6IP蛋白(也称为ALIX)以及脂肪酸合成酶FASN。最近,有研究人员在详细鉴定过的前列腺癌群体中利用质谱分析和组织芯片(TMA)免疫组化技术调查了XPO1和PDCD6IP表达的差异,从而确定它们的诊断和预后值。研究包括了67

Prostate:CD4+ T浸润能够减弱前列腺癌的化疗敏感性

多烯紫杉醇(Doc)化疗在部分前列腺癌(PCa)案例的治疗中是有效的。然而,大多数患者最后都发展为多烯紫杉醇抗性。肿瘤免疫微环境和分泌的细胞因子在化疗抗性的形成过程中具有重要的作用。之前的研究阐释了CD4+ T细胞在前列腺肿瘤微环境中能够促进PCa恶化;同时,研究人员发现CD4+ T细胞浸润在Doc治疗后的肿瘤中增加。然而,它们对PCa化疗敏感性的影响仍旧未知。最进,有研究人员探索了CD4+ T细

基因组研究证实,视网膜母细胞瘤基因突变导致前列腺癌死亡风险增加三倍

有史以来规模最大的晚期前列腺癌基因组学研究表明,在肿瘤中视网膜母细胞瘤基因突变的男性死亡的风险是没有该基因突变患者的三倍,标准治疗复发的可能性几乎是其七倍。